IRVINE, Calif., Oct. 22, 2012 /PRNewswire/ -- GeneTex Inc., a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody that can detect the oxidized form of calmodulin-dependent protein kinase II (CaMKII), which can be used to characterize and diagnose various diseases.
The activation of CaMKII through oxidation is associated with a variety of conditions including heart failure, cardiac arrhythmias, cancer, neurological disease and sepsis. Indeed, CaMKII oxidation increases during myocardial ischemia and infarction, and CaMKII oxidation has been shown to play a pivotal role in cardiac cell death during angiotensin II-mediated apoptosis (Erickson et.al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133(3):462-74 (2008)).
While previous methods of measuring oxidative stress have relied on "bystander" molecules that are not directly implicated in disease pathogenesis, GeneTex's new antibody against oxidized CaMKII will allow researchers to track the oxidation of a biologically active molecule present in blood or biopsy specimens. This antibody has been shown to detect oxidized CaMKII in blood from mice with premature aging due to the knockout of methionine sulfoxide reductase A, mice injected with bacterial endotoxin (a model of sepsis), mice injected with angiotensin II, mice fed a pro-oxidant diet and untreated mice with cancer, as well as mice that had been treated with experimental therapies.
GeneTex is pleased to introduce this antibody against oxidized CaMKII to researchers worldwide. This antibody has been validated for western blotting and immunohistochemistry using both frozen and paraffin-embedded sections and was used to detect oxidized CaMKII in the aforementioned publication in Cell. For additional information on GeneTex's new CaMKII antibody, call toll-free 877-GENETEX (436-3839) or visit http://www.genetex.com/CaMKII-oxidized-antibody-GTX36254.html.
GeneTex is an antibody manufacturing company that was founded by a group of renowned academic scientists in 1997. GeneTex strives to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.